Home Cart Sign in  
Chemical Structure| 1119-34-2 Chemical Structure| 1119-34-2

Structure of H-Arg-OH·HCl
CAS No.: 1119-34-2

Chemical Structure| 1119-34-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

L-Arginine HCl is a substrate of NOS and a nonessential amino acid in human.

Synonyms: (S)-(+)-Arginine hydrochloride; L-Arginine hydrochloride; Levargin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Heiser, Brittany J ; Lewis, Mae M ; Zerankeshi, Meysam Mohammadi ; Netemeyer, Emily K ; Hernandez, Ashlee M ; Marras, Alexander E , et al.

Abstract: Aerosolized lipid nanoparticles (LNPs) delivering mRNA are an attractive strategy for use in local, inhalable therapy to treat patients with lung diseases. However, a major barrier to delivering aerosolized mRNA LNPs is the shear forces encountered during aerosolization. These forces lead to significant morphology changes and subsequent decrease in efficacy of mRNA delivery. To best retain the physicochemical properties of mRNA LNPs during aerosolization, we took a formulation-based strategy to stabilize LNPs. We used a design-of-experiment (DOE) approach to comprehensively screen rationally chosen excipients at multiple concentrations. Excipients were carefully selected based on their use in clinically approved inhaled products or their ability to support lipid membrane properties. These excipients were added to the same mRNA LNP composition after formulation, were subsequently characterized, and used to transfect human lung cells at air–liquid interface. From this systematic screen, we identified that the addition of our lead candidate, poloxamer 188, best stabilizes LNP size throughout aerosolization and enhances mRNA expression after aerosolization. Additional morphological studies of the inclusion of poloxamer 188 in LNPs suggests that the excipient lowers aerosolization induced fusion or aggregation of particles without altering the internal structure. Our results indicate that poloxamer 188 can support aerosolized mRNA LNP delivery by maintaining LNP size and significantly enhancing therapeutic nucleic acid delivery to lung cells.

Purchased from AmBeed: ;

Alternative Products

Product Details of H-Arg-OH·HCl

CAS No. :1119-34-2
Formula : C6H15ClN4O2
M.W : 210.66
SMILES Code : O=C(O)[C@@H](N)CCCNC(N)=N.[H]Cl
Synonyms :
(S)-(+)-Arginine hydrochloride; L-Arginine hydrochloride; Levargin
MDL No. :MFCD00064550
InChI Key :KWTQSFXGGICVPE-WCCKRBBISA-N
Pubchem ID :66250

Safety of H-Arg-OH·HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
AR42J cells 1 mM and 2.5 mM 3 to 12 hours To investigate the effect of L-arginine on NCX1 protein expression. Results showed that 1 mM and 2.5 mM L-arginine treatment for 3 to 12 hours gradually increased NCX1 protein expression, with a more distinct trend in the 1 mM treatment group. Pancreas. 2020 Jan;49(1):111-119.
Porcine alveolar macrophages (PAM) 2, 5, 10, 20, 40 mM 24 hours pretreatment, 72 hours post-infection To study the effect of L-Arginine on ASFV replication, it was found that L-Arginine concentrations above 20 mM significantly promoted ASFV replication Viruses. 2021 Jun 26;13(7):1236.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats L-arginine-induced acute pancreatitis model Intraperitoneal injection 2.5 g/kg Twice, 1 hour apart To investigate the expression changes of NCX1 and NF-κB in the L-arginine-induced acute pancreatitis model. Results showed that between 3 and 12 hours after L-arginine treatment, pancreatic tissue exhibited early to middle phases of acute inflammation, with gradual increases in NCX1 and NF-κB expression. Pancreas. 2020 Jan;49(1):111-119.
C57BL/6 mice L-Arginine-induced acute pancreatitis model Intraperitoneal injection 4 g/kg body weight Hourly injection, a total of two times Induced acute pancreatitis, leading to pancreatic tissue necrosis and inflammatory cell infiltration Nutrients. 2023 Oct 18;15(20):4427
Mice UT-A1/3−/− mice Intravenous injection 1 μg/g BW Single injection To evaluate the effect of L-NAME on renal blood flow in UT-A1/3?/? mice. Results showed that L-NAME caused a significant decrease in renal blood flow, with a greater percentage decrease in UT-A1/3?/? mice compared to wild-type mice. J Am Soc Nephrol. 2005 Jun;16(6):1583-92

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05855330 COVID-19 PHASE2 RECRUITING 2025-06-25 Children's Healthcare of Atlan... More >>ta (CHOA), Egleston, Atlanta, Georgia, 30322, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.75mL

0.95mL

0.47mL

23.73mL

4.75mL

2.37mL

47.47mL

9.49mL

4.75mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories